Polyethylene Oxide Polymers Including Anti-Inflammatory Glycodendrons
First Claim
Patent Images
1. A branched glycopolymer comprising the formula:
- L-[Am]n-X;
wherein L is lactose or a lactose derivative;
A is a polymeric arm comprising a poly(alkylene oxide) where m is a number of monomeric units;
n is a number of branching arms where n=2 to about 100; and
X is a polymer core.
3 Assignments
0 Petitions
Accused Products
Abstract
Poly(ethylene oxide) (PEO) glycodendrimers can serve as multivalent inhibitors of selectin-mediated leukocyte recruitment regulating inflammatory response. Disclosed are compounds and methods relating to functionalized branched glycopolymers. In embodiments, the compounds are capable of modifying cell adhesion events and inflammatory conditions. In a particular embodiment, a multi-arm PEO polymer with sulfated lactose end groups can specifically inhibit interactions involving L-selectin. Also disclosed are methods of synthetic preparation and use.
32 Citations
52 Claims
-
1. A branched glycopolymer comprising the formula:
- L-[Am]n-X;
wherein L is lactose or a lactose derivative;
A is a polymeric arm comprising a poly(alkylene oxide) where m is a number of monomeric units;
n is a number of branching arms where n=2 to about 100; and
X is a polymer core. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 39, 45, 46, 47)
- L-[Am]n-X;
-
20. A method of preparing a branched glycopolymer composition of a structural formula represented by L-[Am]n-X;
- wherein L is a saccharide or a saccharide derivative;
A is a polymeric arm comprising a poly(alkylene oxide) where m is a number of monomeric units;
n is a number of branching arms where n=2 to about 100; and
X is a polymer core. - View Dependent Claims (21, 22, 23, 24, 25, 26)
- wherein L is a saccharide or a saccharide derivative;
-
27. A method of modifying an inflammatory condition comprising administering to a patient in need a compound of the formula L-[Am]n-X;
- wherein L is lactose or a lactose derivative;
A is a polymeric arm comprising a poly(alkylene oxide) where m is a number of monomeric units;
n is a number of branching arms where n=2 to about 100; and
X is a polymer core.
- wherein L is lactose or a lactose derivative;
-
28. A method of modifying a cell adhesion event comprising administering to a patient in need a compound of the formula L-[Am]n-X;
- wherein L is lactose or a lactose derivative;
A is a polymeric arm comprising a poly(alkylene oxide) where m is a number of monomeric units;
n is a number of branching arms where n=2 to about 100; and
X is a polymer core. - View Dependent Claims (33, 34, 35)
- wherein L is lactose or a lactose derivative;
-
29. A method of modifying a selectin-mediated interaction comprising administering to a patient in need a compound of the formula L-[Am]n-X;
- wherein L is lactose or a lactose derivative;
A is a polymeric arm comprising a poly(alkylene oxide) where m is a number of monomeric units;
n is a number of branching arms where n=2 to about 100; and
X is a polymer core. - View Dependent Claims (30, 31, 32)
- wherein L is lactose or a lactose derivative;
-
36. A method of therapy for abdominal aortic aneurysm comprising administering to a patient in need a compound of the formula L-[Am]n-X;
- wherein L is lactose or a lactose derivative;
A is a polymeric arm comprising a poly(alkylene oxide) where m is a number of monomeric units;
n is a number of branching arms where n=2 to about 100; and
X is a polymer core. - View Dependent Claims (38)
- wherein L is lactose or a lactose derivative;
-
37. A medical device treated with a compound of formula L-[Am]n-X;
- wherein L is lactose or a lactose derivative;
A is a polymeric arm comprising a poly(alkylene oxide) where m is a number of monomeric units;
n is a number of branching arms where n=2 to about 100; and
X is a polymer core;
wherein said treated device has at least a portion of a surface that is capable of contacting a patient.
- wherein L is lactose or a lactose derivative;
-
40. A branched glycopolymer comprising the formula:
- L-[A2m2]n2-[A1m1]n1-X;
wherein L is lactose or a lactose derivative;
A1 and A2 are polymeric arms comprising a poly(alkylene oxide) where m1 and m2 are numbers of monomeric units;
n1 and n2 are numbers of branching arms where n1=2 to about 100 and n2=2 to about 100; and
X is a polymer core. - View Dependent Claims (41, 42, 43)
- L-[A2m2]n2-[A1m1]n1-X;
-
44. A branched glycopolymer comprising the formula:
- S-[Am2]n2-[Am1]n1-X;
wherein S is a saccharide or a saccharide derivative;
A is a polymeric arm comprising a poly(alkylene oxide) where m1 and m2 are numbers of monomeric units;
n1 and n2 are numbers of branching arms where n1=2 to about 100 and n2=2 to about 100; and
X is a polymer core.
- S-[Am2]n2-[Am1]n1-X;
-
48. The invention substantially as herein described and illustrated.
-
49. A new compound, substantially as herein described.
-
50. A new use of a compound, substantially as herein described.
-
51. A substance or composition for a new use in a method of treatment, substantially as herein described.
-
52. A new process for preparing a compound, substantially as herein described.
Specification